Examples of OTC Business in a sentence
Subject to Section 5.12(c) with respect to the Dudley facility, such shared service and manufacturing arrangements shall remain in force until the earlier of (i) one year from the Last Closing, in the case of shared services, and three years from the Last Closing, in the case of shared manufacturing, and (ii) such date as the Purchaser and the purchaser of Seller's interest in the OTC Business (or the purchaser of Seller, as the case may be) shall agree.
The Novartis OTC Business is a leader in offering products designed for self-care and prevention of common medical conditions and ailments to enhance people’s overall health and well-being.
The OTC Business Management System, which has its own intellectual property rights, won the third prize of the 2020 Financial Technology Development Award by the People’s Bank of China, with Zhongtai Futures being one of the only two futures companies to win such award.
See Case COMP/M.6280 – P&G/Teva OTC Business, at paragraph 20; Case COMP/M.3751– Novartis/Hexal.
The acquisition of control over Teva's OTC Business is a concentration as it constitutes a part of Teva's assets with market presence, to which a market turnover can be attributed.4 Following the Jurisdictional Notice, sole control is normally acquired on a legal basis where an undertaking acquires a majority of the voting rights or when one shareholder, even if holding a minority stake, has the power to veto strategic decisions.5 IV.
The undertakings concerned have a combined aggregate world-wide turnover of more than EUR 5 000 million6 (P&G EUR 59 544 million, OTC Business of Teva EUR […] million).
There is a meeting of minds between the seller and buyer when they trade in coupons as there is no doubt what the seller is demanding when he/she asks for those “coupons” and the Nation has conveniently allowed this necessary ambiguity to prevail on the understanding that the product is in short supply and that it is necessary to pay a blind eye to this constructive innovation, a typical case of what I have often referred to as a situation of “necessary ambiguity with constructive intent”.
In the context of originator products, the Commission has sometimes resorted to the EPhMRA ATC4 level (see Case COMP/M.3544– Bayer Healthcare/Roche (OTC Business), at paragraphs 15–20).
The acquisition of sole control by P&G over Teva's OTC Business therefore has EU dimension.2 For North America, the parties will set up a separate joint venture (the "NA JV"), which will be controlled by P&G under similar arrangements, and will essentially market P&G's products in the NA.
The transaction will result in Procter & Gamble acquiring sole control over the Company and consequently over Teva's contributed OTC Business and therefore constitutes a concentration within the meaning of Article 3(1)(b) and Article 3(2)(a) of EC Regulation No 139/2004.